Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nanobiotix S.A. (NBTX) SEC filings page brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the Nasdaq Global Select Market. Nanobiotix files reports such as Form 6-K current reports, which often include press releases on clinical, financial, and corporate developments.
Through these filings, investors can access official information on topics such as the JNJ-1900 (NBTXR3) clinical development program, including updates on the global Phase 3 NANORAY-312 study in head and neck squamous cell cancers and other studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Filings may also incorporate details on the company’s collaboration and license agreement with Janssen Pharmaceutica NV for global co-development and commercialization of JNJ-1900 (NBTXR3).
SEC submissions can further describe Nanobiotix’s financing arrangements, including royalty-based agreements with HealthCare Royalty (HCRx) that relate to milestones and royalties on JNJ-1900 (NBTXR3). Investors can review these documents to understand how such transactions interact with expected future payments under the Janssen license agreement.
Because Nanobiotix is also listed on Euronext Paris, some filings reference French regulatory requirements, including disclosures on shares outstanding and voting rights. These items help investors monitor the company’s capital structure and status as a French public company.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the key points of lengthy filings. Users can quickly identify the purpose of each Nanobiotix report, locate information on clinical programs, collaborations, and financing terms, and better understand how individual filings fit into the broader NBTX investment narrative.
NanoBiotix S.A. filed a current report stating that a corporate press release has been issued and is included as Exhibit 99.1 and incorporated by reference into the report. The filing is executed on the company’s behalf by Bart Van Rhijn, the Chief Financial Officer.
Nanobiotix S.A. reported interim results showing Total Revenue of €24.9 million for the six months ended June 30, 2025, driven primarily by a one‑off €21.2 million cumulative catch‑up from a contract modification with Janssen that increased the constrained transaction price. The company recorded a net loss of €5.4 million for the period and held €28.8 million of cash and equivalents as of June 30, 2025. Management estimates current resources finance operations into mid‑2026 and states additional liquidity of €8–10 million will be required over the next 12 months, creating a material uncertainty about going concern. The March 17, 2025 amendment shifts almost full financial responsibility for the NANORAY‑312 Phase 3 trial to Janssen and revises certain milestone amounts, adjusting total deal value to about $2.6 billion with royalties in the low‑teens to low‑20s percentages.